Prosecution Insights
Last updated: October 02, 2026
Application No. 18/096,591

SYSTEMS AND METHODS FOR RESHAPING A HEART VALVE

Final Rejection §103
Filed
Jan 13, 2023
Priority
Mar 14, 2013 — provisional 61/783,420 +3 more
Examiner
ALEMAN, SARAH WEBB
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Boston Scientific Corporation
OA Round
7 (Final)
62%
Grant Probability
Moderate
8-9
OA Rounds
0m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
372 granted / 599 resolved
-7.9% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
33 currently pending
Career history
629
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
49.9%
+9.9% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 599 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/22/2026 and 8/21/2026 has been entered. Response to Arguments Applicant’s arguments, see page 6, filed 7/22/2026, with respect to the 112 rejections, have been fully considered and are persuasive. The amendments to the claims have overcome the previous 112 rejections. Applicant's arguments filed 7/22/2026 have been fully considered but they are not persuasive. In regard to claim 1, Applicant argues that Paul Jr. appears to move the closing member (220) distally in order to reduce the circumference of the grasper (see page 7). In regard to claims 10 and 16, Applicant argues that the cited art does not disclose moving the cylindrical member away from the central ring. Paul teaches that a cylindrical member (closing member 220) is moved axially over the legs (210) in a proximal direction away from the distal end (205 to radially contract the legs inwardly (and thus the attached tissue) (col 11, line 65 to col 12; col 13, line 62 – col 13). Similarly, the cylindrical member (24) taught by Fitz operates to move the tissue engaging members (legs 16) radially inwardly when the cylindrical member (24) moves away from the central ring (20) at the distal end of the device and towards the free ends of the legs at the proximal end of the device (Fig. 1-2). The amendments fail to distinguish over the previous rejections under Bloom/Paul Jr. and Bloom/Fitz, and the rejections have been maintained. Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-9 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over USPAP 2007/0093869 (Bloom et al.) in view of US Patent No. 9,398,902 (Paul, Jr. et al.). Regarding claim 1: Bloom discloses a method of reshaping a valve that involves the deployment of an implantable device (110) having three arms (112) coupled to a central ring (111), the ring (111) located at the distal end of the implant, wherein each arm has a tissue-engaging feature (117) at a proximal end (see Figure 1 and [0022]) arranged and configured for engagement with annular cardiac tissue (see heart valve 205 in Figures 9-13 [0038]). The device is axially controlled by moving it relatively to the delivery catheter (120) [0043]. The device is rotationally controlled by moving portions of the arms (112) radially outwardly/inwardly between three configurations: first contracted configuration (Fig. 7), and expanded configuration (Fig. 1, 8 and 10), and a second contracted configuration of Figures 2 and 13 [0045]. The tissue-engaging features (117) are engaged with the cardiac tissue in Figure 12 and subsequently moved radially inwardly in Figure 13 [0045] to thereby reduce the circumference of the annular cardiac tissue (abstract; [0031]). Since the tissue-engaging features grasp the tissue while moving it radially inwardly, this is considered to meet the requirement of “gathering or pushing” the annular cardiac tissue inwardly. Bloom fails to disclose the step of moving a cylindrical member with respect to the tissue-engaging members and proximally away from the central ring to maintain the reduced circumference of the annular cardiac tissue. Paul discloses another implantable device (22; see Figures 16A-19) having a plurality of legs (210) with tissue-engaging members (213) at their free proximal ends (col 7, lines 36-53), wherein the legs are pivotably coupled to a central ring (204/205) at the distal end of the device (see description of tubular member having a circular cross-section and a central opening for receiving a guidewire 15; column 11, lines 40-52; Figure 20A-B). The legs (210) are biased to a radially outward expanded position of Figure 16B (col 11, lines 60-67). Similar to the method of Bloom, Paul discloses a method of reducing a circumference of tissue by grasping tissue (see edges of tissue V1 around tissue opening A) with the tissue engaging members (teeth 213) and moving the legs radially inwardly to reduce a circumference of the penetrated tissue (Figures 17-19; column 13, line 35 – column 14). Paul teaches that a cylindrical member (closing member 220) is moved axially over the legs (210) in a proximal direction away from the distal end (205 to radially contract the legs inwardly (and thus the attached tissue) and to maintain reduced circumference of the tissue (col 11, line 65 to col 12; col 13, line 62 – col 13). The cylindrical member (220) is engaged with protrusions (215) along the surface of the legs (210) so that the arms can be locked in the closed position of Figure 16B (col 12, lines 6-20). Since both Bloom and Paul are directed towards the concept of moving tissue radially inwardly by contracting legs of a device radially inwardly, one of ordinary skill in the art at the time the invention was made would have found it obvious to combine structures of Paul with the Bloom method. One of ordinary skill in the art would have found it obvious to substitute the slidable cylindrical member (220) taught by Paul for the snap memory shape disclosed by Bloom, wherein the substitution obtains the predictable result of moving the legs radially inwardly. The modification additionally provides the benefit of locking the legs the radial inward position. Regarding claims 2: Bloom and Paul disclose three tissue engaging members and that the tissue-engaging features grasp the tissue while moving it radially inwardly (see Bloom at [0045]; see teeth 213 of Paul at col 13, lines 20-35), therefore reducing the circumference of the annular cardiac tissue (see description of reducing the “compass” of the tissue in Bloom at the abstract; [0006; 0031]; and closing the opening “A” in tissue at column 13, line 35 – column 14 of Paul; Figure 17-19). Regarding claims 3, Paul teaches the cylindrical member (220) is moved axially from the position of Figure 16A to a position of Figure 16B to engage the cylindrical member (220) with the device via protrusions (215) of the (col 11, line 65 to column 12, line 5). Regarding claim 4, Bloom discloses the free ends (117) of the tissue-engaging members (112) are pivotably coupled to the central ring (111) via the length of the members (112). The members pivot radially away from the central ring (111) to engage the cardiac tissue when the device is deployed from the delivery configuration (Figure 7) to an expanded configuration (Figure 8). Regarding claim 5, the legs (112) of the modified Bloom device are moved radially inwardly (not axially) relatively to the cardiac tissue in order to reshape it. The cylindrical member (220) taught by Paul maintains a reduced circumference by moving it relative to tissue-engaging members. Regarding claim 6, Bloom discloses the device is moved by a delivery catheter (120) [0043], which is understood to have a control handle for controlling relative movement of the push tube (126) and holding tube (1240). Paul discloses a delivery device (see 232 and 240 in Figures 17-19) comprising relatively moveable components, wherein it is understood in the art to comprise a control handle. Regarding claims 7-8, Paul teaches that the cylindrical member (220) is moved axially towards the tissue being grasped by the tissue-engaging members (213) (see Figures 16A-B). In regard to claim 9, the tissue-engaging members (112) extend around and are operably coupled to the central ring member (111/204) of modified Bloom. The step of reducing the circumference of tissue can be performed by moving only the annular member taught by Paul, as it acts to reduce the circumference of tissue by radially moving the legs without axially moving the implantable device. Claims 10-12 and 14-20 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over USPAP 2007/0093869 (Bloom et al.) in view of WO 00/07521 (Fitz). Regarding claims 10 and 16: Bloom discloses a method of reshaping a valve that involves the deployment of an implantable device (110) having three arms (112) coupled to a central ring (111), wherein each arm has a tissue-engaging feature (117) at a second end (see Figure 1 and [0022]) arranged and configured for engagement with annular cardiac tissue (see heart valve 205 in Figures 9-13 [0038]). The device is axially controlled by moving it relatively to the delivery catheter (120) [0043]. The device is rotationally controlled by moving portions of the arms (112) radially outwardly/inwardly between three configurations: first contracted configuration (Fig. 7), and expanded configuration (Fig. 1, 8 and 10), and a second contracted configuration of Figures 2 and 13 [0045]. The tissue-engaging features (117) are engaged with the cardiac tissue in Figure 12 and subsequently moved radially inwardly in Figure 13 [0045] to thereby reduce the circumference of the annular cardiac tissue (abstract; [0031]). Since the tissue-engaging features grasp the tissue while moving it radially inwardly, this is considered to meet the requirement of “gathering or pushing” the annular cardiac tissue inwardly. Bloom fails to disclose the implantable device comprises a cylindrical member that is coupled to each of the three or more tissue-engaging members with a linkage, and that the annular member is relative to the central ring to reshape tissue. Fitz discloses another device in Figures 1 and 2 adapted to be deployed in the cardiovascular system (page 7) that comprises a plurality of expandable arms (16) pivotally extending from a central ring (20). Fitz teaches an expansion control mechanism for moving the arms from a compressed configuration of Figure 1 to an expanded configuration of Figure 2, wherein the mechanism a slider (24) slidable along the central axis of a central support (12) and a plurality of linkages (26) coupled to both the slider and arms (16). Fitz indicates this type of control mechanism is similar to a well-known umbrella design (page 6, lines 5-20). This control mechanism provides the operator the ability to manually control the expansion of the arms in order to achieve a desired expanded diameter. Bloom also comprises a relatively movable central wire (128) received in the central passage (111) of the device (110) that is configured to aid in controlling deployment of the device [0037]. One of ordinary skill in the art at the time the invention was made would therefore have found it obvious to incorporate the slider and linkages taught by Fitz with the Bloom device to provide an operator manual control over the precise diameter of radial expansion and contraction of the arms, which allows the implantable device to be adapted for a variety of differences in patient anatomy. The modification involves a combination of known vascular devices according to known methods that obtains a predictable result of a device having a plurality of radially extendable and contractible arms. The slider taught by Fitz corresponds with the claimed “cylindrical member” and operates to move the legs radially inwardly when the cylindrical member moves away from the central ring. In regard to claim 11, the annular member of modified Bloom is engaged with the device in the reshaped configuration. Regarding claim 12: Bloom discloses the tissue-engaging features (117) are engaged with the cardiac tissue in Figure 12 and subsequently moved radially inwardly in Figure 13 [0045] to thereby reduce the circumference of the annular cardiac tissue (abstract; [0031]). In regard to claim 14, Fitz teaches that the tissue-engaging members (16) move radially inwardly without needing to move the central ring (20) axially, as the tissue-engaging members (16) can be contracted by only moving the cylindrical member (24) axially (See Figures 1-2). Regarding claim 15, Bloom teaches the tissue-engaging features are engaged with circumferentially with respect to cardiac tissue and then the implant is moved to reshape the cardiac tissue. Regarding claim 17, Bloom discloses tissue-engaging features (117) pierce tissue [0027] and move the tissue when the device is reshaped in Figure 13 [0045]. Regarding claim 18, the cylindrical member (corresponding to the element 24 of Fitz) is advanced towards the tissue engaging features (117) at the free ends of the legs (see member 24 moved towards free ends of legs 16 in Fitz), which can be considered the proximal direction as required by claim 16. Regarding claim 19, although not explicitly stated, reducing the circumference of the annular cardiac tissue would reduce blood flow therethrough (see description of reducing the “compass” of the tissue in Bloom at the abstract; [0006; 0031]). Regarding claim 20, the legs (112) of the device are moved radially inwardly relative to the cardiac tissue in order to reshape it. Claims 13 is rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Bloom et al. in view of Fitz, and further in view of US Patent No. 9,662,205 (Eidenschink). Bloom and Fitz fail to disclose the step of engaging an annular member with the implantable device to maintain the reduced circumference of the annular cardiac tissue. Eidenschink discloses another device for gathering and securing heart valve tissue (2) that has radially inwardly moving legs (see Figure 5D and 5E). Eidenschink teaches the concept of retaining the legs in the radially inward configuration with a securing ring (130) that is engaged over the legs (see Figures 5F-G) (column 10, lines 35-45). Since both Bloom and Eidenschink are directed towards the concept of gathering tissue radially inwardly, one of ordinary skill in the art at the time the invention was made would have found it obvious to combine the securing ring (130) taught by Eidenschink with the Bloom method, in order to retain the legs and corresponding grasped tissue in a desired radially inward position. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. USPAP 2012/0083804 and USPAP 2006/0195123 disclose devices having a plurality legs that are brought together by a cylindrical member that slides away from a central member to which the legs are connected. All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH WEBB ALEMAN whose telephone number is (571)272-5749. The examiner can normally be reached M, Tu, Th, Fr 9am - 3pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH W ALEMAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Show 17 earlier events
Sep 25, 2025
Response after Non-Final Action
Oct 21, 2025
Non-Final Rejection mailed — §103
Jan 20, 2026
Response Filed
May 22, 2026
Final Rejection mailed — §103
Jul 22, 2026
Response after Non-Final Action
Aug 21, 2026
Request for Continued Examination
Aug 26, 2026
Response after Non-Final Action
Sep 11, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740880
DEVICES AND METHODS FOR TREATING BRANCHING BLOOD VESSELS
4y 0m to grant Granted Sep 22, 2026
Patent 12734056
MEDICAL TUBULAR BODY DELIVERING DEVICE
4y 3m to grant Granted Sep 15, 2026
Patent 12714586
BIFURCATED BALLOON EXPANDABLE STENT ASSEMBLY
4y 1m to grant Granted Aug 25, 2026
Patent 12714291
CHANNEL REPLACEMENT METHOD, ENDOSCOPE, AND PLUG
3y 0m to grant Granted Aug 25, 2026
Patent 12708399
TRANSCATHETER VALVE LACERATION DEVICE AND METHOD
4y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

8-9
Expected OA Rounds
62%
Grant Probability
86%
With Interview (+23.7%)
3y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 599 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month